Soliris Biosimilars Edge Closer In Brazil
Court’s “mailbox” patent decision opens door to competition for Alexion’s Soliris in Brazil.
You may also be interested in...
Switching patients from the very expensive ultra rare disorder drug to ravulizumab will be a key strategy for Alexion if the latter is approved. Recent compelling data in paroxysmal nocturnal hemoglobinuria patients suggests the long-acting C5 complement inhibitor could offer more benefit than its predecessor with more convenient dosing.
While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.
Europe is becoming less competitive in the advanced therapy space, something that is reflected in the number of EU ATMP marketing authorization withdrawals, speakers said at an event organized by the Alliance for Regenerative Medicine.